Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance

ARK Genomic Revolution ETFTrade
Direxion NASDAQ 100 Equal Weighted Index SharesTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? ARK Genomic Revolution ETF trades at $44.6, while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. Which is the better fit depends on your goals.

ARKGQQQE
Sector
Sector/ThematicBroad Market / Factor
52-Week High
$44.55$122.72
52-Week Low
$24.02$96.06

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.

Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.

Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $123.14, up 0.81% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 companies, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the index, which could drive additional inflows. Technical indicators show strong momentum with ADX readings above 25, though RSI suggests some overbought conditions near-term.

The equal-weight approach offers defensive positioning against tech concentration risks while maintaining Nasdaq growth exposure. Key catalysts include continued tech sector strength and index rebalancing benefits. Risks involve Nasdaq volatility and potential sector rotation away from growth stocks. The ETF's structure provides diversification benefits for investors seeking balanced Nasdaq exposure.

Returns comparison

Trailing returns across standard periods

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.

Read more on QQQE